Endovia Health Sciences plans CannEpil FDA submission within a week, seeks pre-submission meeting

• Endovia Health Sciences set plans to submit a CannEpil Z package within a week, targeting an FDA-regulated development pathway.
• A pre-submission conference request to the FDA is planned to clarify the product’s regulatory route and next-stage development steps.
• Strategy includes evaluating CannEpil expansion into additional indications, alongside potential international market opportunities.
• Pipeline buildout planned through reviews of additional cannabinoid formulations, including potential licensing, acquisitions, or strategic collaborations.
• Work underway to finalize expanded financing to fund development activities, potential deals, and operating scale-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endovia Health Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001173), on August 31, 2026, and is solely responsible for the information contained therein.